These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3708602)

  • 1. Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data.
    Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
    Clin Neuropharmacol; 1986; 9(2):165-81. PubMed ID: 3708602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations.
    Sage JI; Mark MH
    Ann Neurol; 1991 Oct; 30(4):616-7. PubMed ID: 1789688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa.
    Quinn N; Marsden CD; Parkes JD
    Lancet; 1982 Aug; 2(8295):412-5. PubMed ID: 6124807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of on/off phenomenon by continuous intravenous infusion of levodopa.
    Quinn N; Parkes JD; Marsden CD
    Neurology; 1984 Sep; 34(9):1131-6. PubMed ID: 6540399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
    Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa methyl ester treatment of Parkinson's disease.
    Juncos JL; Mouradian MM; Fabbrini G; Serrati C; Chase TN
    Neurology; 1987 Jul; 37(7):1242-5. PubMed ID: 3601092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations.
    Hardie RJ; Malcolm SL; Lees AJ; Stern GM; Allen JG
    Br J Clin Pharmacol; 1986 Oct; 22(4):429-36. PubMed ID: 3533125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease.
    Sage JI; Schuh L; Heikkila RE; Duvoisin RC
    Clin Neuropharmacol; 1988 Feb; 11(1):36-44. PubMed ID: 3349496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous levodopa infusions to treat complex dystonia in Parkinson's disease.
    Sage JI; McHale DM; Sonsalla P; Vitagliano D; Heikkila RE
    Neurology; 1989 Jul; 39(7):888-91. PubMed ID: 2472582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intravenous infusion of L-dopa: current prospective therapies].
    Peppe A; De Angelis D; Tolli VS; Rizzo PA; Scoppetta C
    Riv Neurol; 1991; 61(5):197-200. PubMed ID: 1808680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
    Nutt JG; Woodward WR; Hammerstad JP; Carter JH; Anderson JL
    N Engl J Med; 1984 Feb; 310(8):483-8. PubMed ID: 6694694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between L-dopa and lisuride intravenous infusions: a clinical study.
    Ruggieri S; Stocchi F; Carta A; Bravi D; Bragoni M; Giorgi L; Agnoli A
    Mov Disord; 1988; 3(4):313-9. PubMed ID: 3211176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-O-methyldopa and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos JL; Mouradian MM; Serrati C; Chase TN
    Neurology; 1987 May; 37(5):856-9. PubMed ID: 3574690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentration-effect relationship of levodopa in patients with Parkinson's disease.
    Harder S; Baas H; Rietbrock S
    Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease.
    Nilsson D; Hansson LE; Johansson K; Nyström C; Paalzow L; Aquilonius SM
    Acta Neurol Scand; 1998 Mar; 97(3):175-83. PubMed ID: 9531434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients.
    Gancher ST; Nutt JG; Woodward WR
    Neurology; 1987 Jun; 37(6):940-4. PubMed ID: 3587644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-O-methyldopa and the response to levodopa in Parkinson's disease.
    Nutt JG; Woodward WR; Gancher ST; Merrick D
    Ann Neurol; 1987 Jun; 21(6):584-8. PubMed ID: 3606046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.